Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A SHR0302 BA Study on Healthy Subjects
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06202612
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06198556
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06196580
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06173999
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT06169995
- Locations
- 🇨🇳
The Affiliated Hospital Of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06168929
- Locations
- 🇨🇳
Central Hospital Affilated to Shandong First Medical University, Jinan, Shandong, China
A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT06144060
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT06139393
Assessment of Gastric Emptying by SHR20004 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06137469
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1200
- Registration Number
- NCT06126640
© Copyright 2024. All Rights Reserved by MedPath